Jens Ingvarsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jens Ingvarsson has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Viktor Grut
Department of Clinical Sciences, Neurosciences Umeå University Umeå Sweden
4 shared publications Peter Sundström
Department of Clinical Sciences, Neurosciences, Umeå University , 90187 Umeå
3 shared publicationsStaffan Nilsson
Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg , Gothenburg
3 shared publicationsTim Waterboer
Division of Infections and Cancer Epidemiology German Cancer Research Center Heidelberg Germany
3 shared publicationsTomas Olsson
Department of Clinical Neuroscience, Karolinska Institutet , 17177 Stockholm
3 shared publicationsBirgitta E Michels
Division of Infections and Cancer Epidemiology, German Cancer Research Center , 69120 Heidelberg
2 shared publications
Latest Publications
- Open Access
- 22 August 2026
- Published by Oxford University Press (OUP) in Brain
Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome
Epstein-Barr virus (EBV) is a critical risk factor for multiple sclerosis (MS), but the pathogenic mechanisms remain elusive. To clarify its role in MS, we examined the sequence of EBV-related antibody responses over a broad period before the clinical onset of MS, from early childhood to middle age. A nested case-control study was performed by linking Swedish MS registries with biobanks to identify pre-symptomatic samples from individuals who later developed MS and matched controls. Leveraging these samples, we analysed the immune responses to EBV in and before the prodromal phase of MS. Antibodies against EBV (viral capsid antigen, VCA; EBV nuclear antigen 1, EBNA1; early antigen-diffuse, EA-D) and the putative autoantibody target Anoctamin 2 (ANO2) were quantified by immunoassay. Serum neurofilament light chain (S-NfL), a marker of axonal injury, was quantified by single-molecule array. Ratios of these markers were calculated within each matched case-control set, plotted against time to the clinical onset of MS, and analysed with Loess regression to visualise the temporal order of events on group level. Samples from 981 cases and 1278 controls were included. Median age at blood sampling was 22 years and 32% of the participants were children or adolescents. The median time from the blood sample to the clinical onset of MS was 9 years. On the group level, we observed the following sequence of events: Seroreactivity against lytic EBV antigens (VCA-IgG, VCA-IgM, EA-D) – characterizing primary EBV infection and reactivation – were significantly higher in cases than in controls more than 20 years before MS onset and onwards. Increased seroreactivity against the latent antigen EBNA1 was observed 15 years before onset, followed by increased ANO2 seroreactivity from 9 years and onwards. Finally, a significant elevation of S-NfL was observed from 7 years prior to MS onset. These findings demonstrate a more extensive lytic EBV infection in the decades before MS onset, consistent with the hypothesis that EBV is a driver of MS development. The sequence of increasing seroreactivity against EBNA1 and ANO2 was closely followed by biochemical signs of neuroaxonal injury, suggesting epitope spreading from EBNA1 before the subclinical onset of neuroaxonal damage. This sequence of events supports the hypothesis that EBV infection promotes autoreactive immune cells contributing to MS pathogenesis.
- 22 August 2026
- Published by Oxford University Press (OUP) in Brain
Open AccessLytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome
Epstein-Barr virus (EBV) is a critical risk factor for multiple sclerosis (MS), but the pathogenic mechanisms remain elusive. To clarify its role in MS, we examined the sequence of EBV-related antibody responses over a broad period before the clinical onset of MS, from early childhood to middle age. A nested case-control study was performed by linking Swedish MS registries with biobanks to identify pre-symptomatic samples from individuals who later developed MS and matched controls. Leveraging these samples, we analysed the immune responses to EBV in and before the prodromal phase of MS. Antibodies against EBV (viral capsid antigen, VCA; EBV nuclear antigen 1, EBNA1; early antigen-diffuse, EA-D) and the putative autoantibody target Anoctamin 2 (ANO2) were quantified by immunoassay. Serum neurofilament light chain (S-NfL), a marker of axonal injury, was quantified by single-molecule array. Ratios of these markers were calculated within each matched case-control set, plotted against time to the clinical onset of MS, and analysed with Loess regression to visualise the temporal order of events on group level. Samples from 981 cases and 1278 controls were included. Median age at blood sampling was 22 years and 32% of the participants were children or adolescents. The median time from the blood sample to the clinical onset of MS was 9 years. On the group level, we observed the following sequence of events: Seroreactivity against lytic EBV antigens (VCA-IgG, VCA-IgM, EA-D) – characterizing primary EBV infection and reactivation – were significantly higher in cases than in controls more than 20 years before MS onset and onwards. Increased seroreactivity against the latent antigen EBNA1 was observed 15 years before onset, followed by increased ANO2 seroreactivity from 9 years and onwards. Finally, a significant elevation of S-NfL was observed from 7 years prior to MS onset. These findings demonstrate a more extensive lytic EBV infection in the decades before MS onset, consistent with the hypothesis that EBV is a driver of MS development. The sequence of increasing seroreactivity against EBNA1 and ANO2 was closely followed by biochemical signs of neuroaxonal injury, suggesting epitope spreading from EBNA1 before the subclinical onset of neuroaxonal damage. This sequence of events supports the hypothesis that EBV infection promotes autoreactive immune cells contributing to MS pathogenesis.
- Open Access
- 16 April 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (4) , e70094
Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis
Objective: Several factors have been associated with altered risk of developing multiple sclerosis (MS). Epstein–Barr virus (EBV) is the critical risk factor for MS, but recent studies indicate that human herpesvirus 6A (HHV‐6A) and cytomegalovirus (CMV) are involved in MS aetiopathogenesis. We recently reported an association between rubella virus (RV) envelope protein 1 (E1) seropositivity and the risk of developing MS. Here, we aimed to further explore this association. Methods: Bio‐banked blood samples collected before the onset of MS from 981 cases and 1278 matched controls were analysed for antibodies against RV envelope proteins 1 and 2 (E2), and serum‐neurofilament light chain (S‐NfL), a marker for axonal injury. The association between RV and MS was analysed with conditional logistic regression, calculating odds ratios (OR) with 95% confidence intervals (CI). Results: Rubella E1 seropositivity was significantly associated with a higher risk of MS development, even when adjusting for EBV, CMV and HHV‐6A serostatus (OR = 1.67, 95% CI 1.29–2.14, P < 0.001). We also observed an increase in seroreactivity against RV E1 before an increase in S‐NfL in MS cases, indicating that increased RV E1 seroreactivity precedes axonal injury in the MS prodrome at group‐level. There was no association between RV E2 serostatus and MS risk. The association between RV E1 serostatus and MS risk remained similar when the analysis was restricted to unvaccinated participants (OR = 1.78, 95% CI 1.07–2.98, P = 0.028). Conclusions: Our results support a broadening of the viral hypothesis in MS, arguing for further studies on the neurotropic RV in MS aetiology.
- 16 April 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (4) , e70094
Open AccessSeropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis
Objective: Several factors have been associated with altered risk of developing multiple sclerosis (MS). Epstein–Barr virus (EBV) is the critical risk factor for MS, but recent studies indicate that human herpesvirus 6A (HHV‐6A) and cytomegalovirus (CMV) are involved in MS aetiopathogenesis. We recently reported an association between rubella virus (RV) envelope protein 1 (E1) seropositivity and the risk of developing MS. Here, we aimed to further explore this association. Methods: Bio‐banked blood samples collected before the onset of MS from 981 cases and 1278 matched controls were analysed for antibodies against RV envelope proteins 1 and 2 (E2), and serum‐neurofilament light chain (S‐NfL), a marker for axonal injury. The association between RV and MS was analysed with conditional logistic regression, calculating odds ratios (OR) with 95% confidence intervals (CI). Results: Rubella E1 seropositivity was significantly associated with a higher risk of MS development, even when adjusting for EBV, CMV and HHV‐6A serostatus (OR = 1.67, 95% CI 1.29–2.14, P < 0.001). We also observed an increase in seroreactivity against RV E1 before an increase in S‐NfL in MS cases, indicating that increased RV E1 seroreactivity precedes axonal injury in the MS prodrome at group‐level. There was no association between RV E2 serostatus and MS risk. The association between RV E1 serostatus and MS risk remained similar when the analysis was restricted to unvaccinated participants (OR = 1.78, 95% CI 1.07–2.98, P = 0.028). Conclusions: Our results support a broadening of the viral hypothesis in MS, arguing for further studies on the neurotropic RV in MS aetiology.
- Open Access
- 18 December 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (1)
Human herpesvirus 7 and the risk of developing multiple sclerosis
Epstein–Barr virus is now regarded as the critical risk factor for multiple sclerosis. However, Cytomegalovirus and human herpesvirus 6A have also been associated with altered multiple sclerosis risk, suggesting a multifactorial aetiology. Here, we present the first large-scale study of the association between human herpesvirus 7 and the risk of developing multiple sclerosis. A nested case-control study was performed by crosslinking Swedish registries and biobanks, identifying blood samples from 981 cases who later developed multiple sclerosis and 1278 matched controls. Serological testing was performed with a multiplex immunoassay. The association between viral serostatus and the risk of developing multiple sclerosis was analysed with conditional logistic regression, calculating an odds ratio with 95% confidence interval. Interactions between antibodies against human herpesvirus 7 and the Epstein–Barr virus nuclear antigen 1 regarding multiple sclerosis risk were analysed on the additive scale. Serological evidence of human herpesvirus 7 infection was associated with a higher risk of developing multiple sclerosis: odds ratio = 2.2 (95% confidence interval = 1.8–2.7), P < 0.001. The results remained similar when adjusting for cytomegalovirus, Epstein–Barr virus and human herpesvirus 6A serostatus. Synergistic interactions between human herpesvirus 7 and Epstein–Barr virus nuclear antigen 1 seroreactivity were observed: attributable proportion due to interaction = 0.51 (95% confidence interval = 0.34–0.68). These results suggest that human herpesvirus 7 could be a contributing factor in multiple sclerosis aetiology.
- 18 December 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (1)
Open AccessHuman herpesvirus 7 and the risk of developing multiple sclerosis
Epstein–Barr virus is now regarded as the critical risk factor for multiple sclerosis. However, Cytomegalovirus and human herpesvirus 6A have also been associated with altered multiple sclerosis risk, suggesting a multifactorial aetiology. Here, we present the first large-scale study of the association between human herpesvirus 7 and the risk of developing multiple sclerosis. A nested case-control study was performed by crosslinking Swedish registries and biobanks, identifying blood samples from 981 cases who later developed multiple sclerosis and 1278 matched controls. Serological testing was performed with a multiplex immunoassay. The association between viral serostatus and the risk of developing multiple sclerosis was analysed with conditional logistic regression, calculating an odds ratio with 95% confidence interval. Interactions between antibodies against human herpesvirus 7 and the Epstein–Barr virus nuclear antigen 1 regarding multiple sclerosis risk were analysed on the additive scale. Serological evidence of human herpesvirus 7 infection was associated with a higher risk of developing multiple sclerosis: odds ratio = 2.2 (95% confidence interval = 1.8–2.7), P < 0.001. The results remained similar when adjusting for cytomegalovirus, Epstein–Barr virus and human herpesvirus 6A serostatus. Synergistic interactions between human herpesvirus 7 and Epstein–Barr virus nuclear antigen 1 seroreactivity were observed: attributable proportion due to interaction = 0.51 (95% confidence interval = 0.34–0.68). These results suggest that human herpesvirus 7 could be a contributing factor in multiple sclerosis aetiology.
- Open Access
- 18 July 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (10) , e16387
Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis
Background: Multiple sclerosis (MS) is a demyelinating disease affecting millions of people worldwide. Hereditary susceptibility and environmental factors contribute to disease risk. Infection with Epstein–Barr virus (EBV) and human herpesvirus 6A (HHV‐6A) have previously been associated with MS risk. Other neurotropic viruses, such as rubella virus (RV), are possible candidates in MS aetiopathogenesis, but previous results are limited and conflicting.Methods: In this nested case–control study of biobank samples in a Swedish cohort, we analysed the serological response towards RV before the clinical onset of MS with a bead‐based multiplex assay in subjects vaccinated and unvaccinated towards RV. The association between RV seropositivity and MS risk was analysed with conditional logistic regression.Results: Seropositivity towards RV was associated with an increased risk of MS for unvaccinated subjects, even when adjusting for plausible confounders including EBV, HHV‐6A, cytomegalovirus and vitamin D (adjusted odds ratio [AOR] = 4.0, 95% confidence interval [CI] 1.8–8.8). Cases also had stronger antibody reactivity towards rubella than controls, which was not seen for other neurotropic viruses such as herpes simplex or varicella zoster. Furthermore, we observed an association between RV seropositivity and MS in vaccinated subjects. However, this association was not significant when adjusting for the aforementioned confounders (AOR = 1.7, 95% CI 1.0–2.9).Conclusions: To our knowledge, these are the first reported associations between early RV seropositivity and later MS development. This suggests a broadening of the virus hypothesis in MS aetiology, where molecular mimicry between rubella epitopes and human central nervous system molecules could be an attractive possible mechanism.
- 18 July 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (10) , e16387
Open AccessRubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis
Background: Multiple sclerosis (MS) is a demyelinating disease affecting millions of people worldwide. Hereditary susceptibility and environmental factors contribute to disease risk. Infection with Epstein–Barr virus (EBV) and human herpesvirus 6A (HHV‐6A) have previously been associated with MS risk. Other neurotropic viruses, such as rubella virus (RV), are possible candidates in MS aetiopathogenesis, but previous results are limited and conflicting.Methods: In this nested case–control study of biobank samples in a Swedish cohort, we analysed the serological response towards RV before the clinical onset of MS with a bead‐based multiplex assay in subjects vaccinated and unvaccinated towards RV. The association between RV seropositivity and MS risk was analysed with conditional logistic regression.Results: Seropositivity towards RV was associated with an increased risk of MS for unvaccinated subjects, even when adjusting for plausible confounders including EBV, HHV‐6A, cytomegalovirus and vitamin D (adjusted odds ratio [AOR] = 4.0, 95% confidence interval [CI] 1.8–8.8). Cases also had stronger antibody reactivity towards rubella than controls, which was not seen for other neurotropic viruses such as herpes simplex or varicella zoster. Furthermore, we observed an association between RV seropositivity and MS in vaccinated subjects. However, this association was not significant when adjusting for the aforementioned confounders (AOR = 1.7, 95% CI 1.0–2.9).Conclusions: To our knowledge, these are the first reported associations between early RV seropositivity and later MS development. This suggests a broadening of the virus hypothesis in MS aetiology, where molecular mimicry between rubella epitopes and human central nervous system molecules could be an attractive possible mechanism.